2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 184

An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease
Abstract Number: 409

An Evaluation of Absolute Neutrophil Count As a Biomarker of Inflammatory and Clinical Disease Activity in Baricitinib-Treated Patients
Abstract Number: 1681

An Evaluation of Two Novel Techniques Utilising a Smartphone Digital Camera in the Assessment of Nailfold Capillaries in Suspected Scleroderma-Spectrum Disorders: A Single-Center Cross-Sectional Study
Abstract Number: 2196

An Exploratory Analysis of Physical Activity Levels and the Presence of Bone Marrow Lesions in Adults with Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 1107

An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Abstract Number: 2100

An International Consensus Exercise to Develop Candidate Items for Classification Criteria in Relapsing Polychondritis
Abstract Number: 745

An International Qualitative Research Study Exploring the Patient Experience of Raynaud’s Phenomenon in Systemic Sclerosis
Abstract Number: 398

An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Abstract Number: 2273

An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies
Abstract Number: 645

An Oral Tyk2 Inhibitor Effectively Suppresses the Development of Murine Th17 Cells In Vivo and Prevents Joint Damage in Experimental Ankylosing Spondylitis
Abstract Number: 250

An Ultrasonographic Study for Investigating Relationships with the Signs of Uric Deposition and Bone Erosion in Patients with Hyperuricemia
Abstract Number: 298

Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans
Abstract Number: 2224

Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain: Results of a Randomized, Controlled, Proof-of-Concept Trial
Abstract Number: 2876

Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Abstract Number: 2650

Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].